Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market.
IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)
The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION
c/o Interexperts SA
Rue des Pierres-du-Niton 17
1207 Geneva, Switzerland
Telephone: +32 (0)2 5346607
E-mails:
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
This email address is being protected from spambots. You need JavaScript enabled to view it.